SCHEMBL4452954

SCHEMBL4452954

O=C(NC(Cc1cccc(O)c1)C(=O)N1CCC2OCC(=O)C21)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.60

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CTSK P43235 9/20 0.60
CTSS P25774 6/20 0.56
CTSL P07711 5/20 0.56
CTSV O60911 4/20 0.56
HPGDS O60760 1/20 0.38
TSHR P16473 1/20 0.38
PPARG P37231 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4449566 0.92 CTSK (0.72) CTSKCTSSCTSLCTSV
SCHEMBL13677198 0.92 CTSK (0.72) CTSKCTSSCTSLCTSV
SCHEMBL5260950 0.92 CTSK (0.72) CTSKCTSSCTSLCTSV
SCHEMBL6801627 0.91 CTSS (0.67) CTSKCTSSCTSLCTSVHPGDS
SCHEMBL4452965 0.91 CTSK (0.65) CTSKCTSSCTSLCTSV
SCHEMBL5258427 0.90 CTSK (0.55) CTSKCTSSCTSLCTSV
SCHEMBL4446408 0.90 CTSK (0.57) CTSKCTSSCTSLCTSVHPGDS
SCHEMBL4458895 0.90 CTSK (0.64) CTSKCTSSCTSLCTSVPPARG
SCHEMBL5254982 0.88 CTSK (0.60) CTSKCTSSCTSLCTSVHPGDS
SCHEMBL14097286 0.88 CTSK (0.58) CTSKCTSSCTSLCTSVHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247471-A1 INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES AMURA THERAPEUTICS LTD. (GB) 2009-10-01 US disclosed
US-7425562-B2 Inhibitors of cruzipain and other cysteine proteases AMURA THERAPEUTICS LTD. (GB) 2008-09-16 US disclosed
EP-1362052-B1 INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2007-03-07 EP disclosed
US-20040138250-A1 Inhibitors of cruzipain and other cysteine proteases GRUNENTHAL GMBH (DE) 2004-07-15 US disclosed
EP-1362052-A1 INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES Amura Therapeutics Limited (GB) 2003-11-19 EP disclosed
WO-2002057270-A1 INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES AMURA THERAPEUTICS LIMITED (GB) 2002-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138250-A1 Inhibitors of cruzipain and other cysteine proteases CPN1, CTRL, CPA1 CTSK 62/4885CTSS 39/4885CTSL 23/4885
US-20090247471-A1 INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES CPN1, CTRL, CPA1 CTSK 45/4885CTSS 21/4885CTSL 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.